Sales of the company’s spinal implants and heart defibrillators, which account for about 40 percent of total sales, had been weak for more than a year and were down 5 percent this quarter as well. Overall revenue reached $4.13 billion and was boosted by sales of heart valves, stents and other upgraded products.
Related Articles on Medical Devices:
FDA Clears Aptus Endosystems EndoStapling System
Doctors Question the Value of Robot-Assisted Surgery
FDA Studying New Heart Stents that Stretch After Implantation
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
